Novartis trial results could spell trouble for Regeneron

Head-to-head late-stage clinical trials published on Tuesday showed that a Novartis (NYSE:NVS) drug to treat patients with neovascular age-related macular degeneration doesn’t need to be injected as frequently as a rival drug from competitor Regeneron (NSDQ:REGN).
Analysts reportedly said the data gives Novartis’ treatment, RTH258, a competitive edge compared to its rival therapies.
Get the full story at our sister site, Drug Delivery Business News.
The post Novartis trial results could spell trouble for Regeneron appeared first on MassDevice.

Source: Mass Device - June 21, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Optical/Ophthalmic Pharmaceuticals Wall Street Beat Allergan Inc. Novartis Regeneron Roche Source Type: news